CMC Analytical Development Scientist; ADCs & Proteins

The CMC laboratory team leads and supports the development and optimization of analytical methods for our lead projects, while providing a high-standard platform for the analysis and characterization of a variety of different internal projects. Together with the whole CMC department, we plan and analyze experiments, which support and facilitate the transition from R&D/pre-clinical projects to the CMC stage, and help to develop our technology further.

• Development of new analytical methods supporting the CMC process of our lead candidates
• Lead planning, execution and analysis of experiments in the context of CMC projects
• Contribute to the stage appropriate characterization of ADC assets
• Contribute to the operation and maintenance of laboratory equipment
• Contribute to routine tasks supporting the analytical platform

Must-Have Qualifications:

Experience with Mass spectrometry, ideally with Proteins

Fluent in English (spoken/written)

Strong experience with analytical instruments and biochemical assays (HPLC, Mass spectrometry, ELISA, SDS-page etc.), including the relevant software

Nice-to-Have Qualifications :

Experience with GMP environment is a plus

Previous experience with antibodies, ADCs and conjugation techniques is a plus

At Tubulis, curiosity and innovation drive us to transform cancer treatment. We are a fast-growing biotech where science meets passion—and where you have the chance to grow with us.

• Impact that matters:
  Contribute to breakthrough therapies.
• Global mindset:
  Work in an international, diverse team.
• Grow & thrive:
  Develop your career in a supportive, fast-moving environment.
• Innovation every day:
  Push boundaries with cutting-edge science.

Tubulis is a clinical stage biotech company that generates uniquely matched antibody-drug conjugates (ADCs) with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models. We recently closed on a Series C fundraising round totaling €344M (US $401M).

The development of novel, effective and safe therapies for the treatment of cancer is one of the main challenges for modern medicine. We want to drive this process forward. The main goal of Tubulis is to become a leading company in the field of targeted therapeutics and ADCs. With a strong team, our own technologies and innovative therapeutic concepts, we are ushering in a new era in the ongoing fight against cancer and share the vision of helping patients world-wide.

Be part of a multidisciplinary and focused team, that works towards getting novel promising ADCs to patients with solid and hematological cancers.